Loading
Life sciences · Journal article
Acs Infectious Diseases · July 27, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review article that surveys antimicrobial peptide research from Latin American sources and their engineering approaches, without presenting quantified experimental results or clinical evidence. It identifies the region as a source of biodiversity-derived AMPs and discusses design strategies (rational design, SAR, AI/machine learning) but does not evaluate the efficacy or clinical utility of any specific AMP.
Journal article. Natural and synthetic antimicrobial peptides sourced from Latin American organisms (amphibians, reptiles, invertebrates, microorganisms) and their engineering variants.. Latin America, including South America.
Latin America accounts for approximately 60% of the world's total biodiversity, fueling research into natural product-derived antimicrobial peptides. AMPs from the region have been modified and refined over the past decade using rational design, SAR studies, and AI/machine learning approaches. Studies have identified AMPs from amphibians, reptiles, invertebrates, and microorganisms from South America with diverse biological activities.
No primary efficacy or safety data, clinical trial outcomes, or patient populations reported.
This review does not present clinical trial data or direct evidence that would guide clinical decision-making. It surveys the landscape of AMP research in Latin America and identifies potential directions for drug development but does not quantify efficacy, safety, or clinical outcomes.
This is a narrative mini-review that surveys the landscape of antimicrobial peptide discovery and engineering in Latin America, raising questions and examining contributions rather than presenting primary evidence or clinical outcomes.
As stated by the source record.
Quoted from the source exactly as published.
This review does not present clinical trial data or direct evidence that would guide clinical decision-making. It surveys the landscape of AMP research in Latin America and identifies potential directions for drug development but does not quantify efficacy, safety, or clinical outcomes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Latin America’s biodiversity accounts for approximately 60% of the world’s total, fueling scientific research into natural products, a highly relevant area in drug discovery to this day. This is accompanied by an increasing number of antimicrobial peptides (AMPs) derived from natural products in the region, which over the past decade have been redesigned through modifications, enhancements, and refinements of their physicochemical properties and antimicrobial potency, using approaches that range from rational design and structure–activity relationship (SAR) studies to artificial intelligence and machine learning methodologies. AMPs and their derivatives represent a vast chemical space with potential for antibacterial, antifungal, antiviral, and antiparasitic therapies, with emerging applications beyond infectious diseases. Over the years, studies have identified these peptides from a wide range of sources, including amphibians, reptiles, invertebrates, and microorganisms from South America, highlighting their diverse biological activities. This raises important questions about whether Latin America is a fertile source of inspiration for the development of AMPs. It also prompts an examination of the region’s historical and ongoing contributions to the field of natural and synthetic AMPs with anti-infective potential. Additionally, it highlights the need to assess the region’s progress in keeping pace with the recent advancements in engineering AMPs to combat resistant bacteria. This mini-review addresses these topics and related issues, exploring Latin America’s discoveries, challenges, and innovations in AMPs and their applications, particularly in anti-infective agents.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.